Good day, and welcome to the P3 Health Partners Fourth Quarter 2023 Earnings Conference Call. Please note, today's event is being recorded. I would now like to turn the conference over to Ryan Halsted. Please go ahead, sir.

Thank you, operator, and thank you for joining us today. Before we proceed with the call, I would like to remind everyone that certain statements being made during this call are forward-looking statements under U.S. federal securities laws, including statements regarding our financial outlook and long-term target. These forward-looking statements are only predictions and are based largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. Additional information concerning factors that could cause actual results to differ from statements made on this call is contained in our periodic reports filed with the SEC. The forward-looking statements made during this call speak only as of the date hereof, and the company undertakes no obligation to update or revise the forward-looking statements. We will refer to certain non-GAAP financial measures on this call, including adjusted operating expense, adjusted EBITDA, adjusted EBITDA per member per month, medical margin, medical margin per member per month, medical margin per member per month for persistent lives, and cash burn. These non-GAAP financial measures are in addition to and not a substitute or superior to the measures of financial performance prepared in accordance with GAAP. There are a number of limitations related to the use of these non-GAAP financial measures. For example, other companies may calculate similarly titled non-GAAP financial measures differently. Please refer to the appendix of our earnings release for a reconciliation of these non-GAAP financial measures to the most directly comparable GAAP measures. Information presented on this call is contained in the press release that we issued today and in our SEC filings, which may be accessed from the Investors page of the P3 Health Partners website. I will now turn the call over to Dr. Abdou, CEO and Co-Founder of P3.

Thanks, Ryan, and welcome, everyone, to our year-end 2023 conference call. We would like to update you on our fourth quarter and full year 2023 financial results as well as provide further thoughts on 2024. Our momentum remains robust. We are reaffirming 2024 guidance based on several key observations in the early part of the year. Number one, starting with our membership, the annual enrollment period was a success, and our January membership increased by approximately 11% from December to account for approximately 121,000 Medicare Advantage and Medicare ACO Reach lives. Number two, consistent with our stated objective of disciplined and purposeful growth, we have broadened our service area by expanding into two adjacent counties in Arizona and six contiguous counties in Oregon, bringing us to a total of 23 counties at the start of 2024. Number three, our revenue in 2023 grew approximately 21% year-over-year. Our per member per month funding was up approximately 16% year-over-year, and despite the challenges other sectors have voiced around V24 to V28 and declines in reimbursement, as we indicated in earlier commentary, we are realizing an increase in our funding. Number four, medical margin improved by 118% from 2022 to 2023. And you will hear from Atul that the increase in utilization is in part attributed to the EBITDA. But what gives me further confidence in 2024 is that medical claim expense decreased by 26% in January from December, returning to a normalized level. Number five, the initiatives we put in place to enhance operational efficiency continue to materialize, as platform expense came down by 32% year-over-year, to be a high single-digit percentage of revenue for the year as previously indicated. Our fourth quarter trend is even more impressive, and we believe it will establish the baseline for 2024. Number six, considering the adjustment to EBITDA were mostly non-cash items, our net cash used in operations significantly improved over the first half of the year. Number seven, we continue towards our inflection point, and we expect to become EBITDA positive in 2024, consistent with our previous guidance of positive $20 million to $40 million by year-end. Number eight, we continue to advance a robust pipeline of growth opportunities and expect positive development across multiple strategic partnerships in the coming quarters. And finally, number nine, the team remains highly motivated to deliver in 2024, and, combined with our early data points, we are confirming and reaffirming our previous 2024 guidance. In conclusion, we believe the demand for the P3 model is at an all-time high, and we believe that our demonstrated ability to manage the medical margin, improve funding, and grow membership are driving this demand. We remain confident in 2024 results based on the utilization trends we are seeing early in the year despite the increase in December 2023. Our payer, provider, and health system discussions are ongoing, including potential joint venture and strategic partnership opportunities. I am encouraged by the tremendous strides the P3 team continues to make on the clinical and operational sides. I am confident in our ability to achieve profitability this year and scale in the coming years. With that, I would like to turn it over to Atul Kavthekar, our Chief Financial Officer.

Thanks, Sherif. Sherif hit the highlights, but I want to provide a bit more detail on the fourth quarter and the full year 2023 results, which brought us below our full year EBITDA guidance we confirmed in early January 2024. I will discuss in some detail some of the new information we received in February of 2024 that caused these changes to Q4, but I'll also speak about the encouraging factors around our 2024 expectations and the reason we are so excited about P3's future. First, let me walk you through the fourth quarter and full year 2023 numbers. Top line results in 2023 were strong as the team executed and delivered revenue of $1.266 billion, representing 21% growth and above our guidance range. On a PMPM basis, revenues grew by approximately 15% over 2022. In the fourth quarter, we had revenue of $347 million, a 34% increase over the fourth quarter of 2022. As we've discussed on previous calls, we developed a model to estimate the amounts we expect to receive related to our 2023 wrap, paid in June or July of 2024. Going forward, we expect to be able to accrue our estimated final sweep amounts for the 2024 payment year that will be paid in mid-2025, in the fourth and potentially the third quarter of 2024. In 2023, as Sherif mentioned, our medical margin, which represents the amounts earned from capitation revenue after medical claims expense, improved 118% over the prior year to $135 million or $108 on a PMPM basis. We believe that despite the large adjustments to our reserve taken in the quarter, which I'll discuss in more detail, the positive trend in this critical metric is continued proof that our model works and is only improving. To that end, we continue to optimize our provider and payer networks to enhance medical margins going forward. Our platform support costs are another demonstration of our commitment to driving operating leverage and shareholder value and have continued to decrease as a percentage of revenue. In fact, we decreased our platform costs as a percentage of revenues from around 15% in 2021 and 11% in 2022 to approximately 8% for the full year 2023, consistent with the guidance of high single digits we've provided in the past. Adjusted EBITDA loss was $86 million in 2023 compared to an adjusted EBITDA loss of $128 million in the prior year. On a per member per month basis, adjusted EBITDA loss was $68, an improvement of $39 PMPM compared to the prior year, as we successfully improved margins and lowered costs on a per member basis. For the quarter, adjusted EBITDA loss was $44 million or approximately $138 on a PMPM basis. Now I'd like to provide more details around the two main items that made up roughly $40 million of Q4 2023 adjustments that drove our miss relative to our EBITDA guidance. The single biggest factor accounting for approximately $30 million is the combined impact of increased utilization in December among some of our health plans, along with an increase in our claims reserve at the end of 2023. In the past few weeks, we determined that it would be prudent and appropriate to increase our reserves by approximately $23 million to reflect greater conservatism in our allowances for claims, which have not yet been presented. In addition to this, we recognized incremental medical claims expense of approximately $7 million for higher-than-expected utilization by some of our health plans for December of 2023, which was presented to us in February of 2024. Although our own estimates of future claims related to those dates of service were lower, we chose to maintain our recent protocol of booking based on the estimates of our independent actuary. Over the next several quarters, we will work with our actuaries to observe the actual claims experience and reevaluate our reserve estimates. It is worth noting that medical margins and adjusted EBITDA would benefit in the future to the extent that trends on actual claims are favorable when compared to the estimates reflected on the balance sheet in the fourth quarter. The other significant factor reflected in the quarter's results relates to the write-down of approximately $10 million of settlement receivables, which are open and subject to continuing dialogue. We are engaged in a review process with our payer partners regarding the resolution of these amounts. However, because the resolution of those discussions is subject to an ongoing review, we've taken a conservative approach consistent with GAAP and have deferred recognition of that revenue until such time the final disposition is reached. Shifting to our 2024 outlook. Early 2024 data from our health plan suggests a strong start to the year. A few specific examples on the membership front, early indicators for our annual enrollment period were strong. By the end of January, we already recognized about 121,000 Medicare at-risk members. This is already approaching the lower end of our full year guidance of 125,000 to 135,000 members by the end of 2024. With our plans for expanding our network over the course of the calendar year, we believe we are well positioned to meet and potentially exceed our guidance. Our early indicators of funding also showed strong improvement over the prior year and are proving to line up well with our initial guidance assumptions. This has been verified by reports received to date from our health plan partners and is another point of validation of our expectations. Our California market, which is 100% delegated, showed particularly strong growth in funding as evidenced by our cash receipts. With regards to medical expense, Dr. Amir Bacchus, our Chief Medical Officer, and Bill Bettermann, our Chief Operating Officer, will go through this in more detail. We observed a clear return to normalized seasonally adjusted metrics for two of our KPIs, admits per 1,000 and emergency department visits per 1,000. This is a clear indicator of recovery for both of these metrics from elevated levels in December. So, to summarize, our full year fiscal 2024 guidance included Medicare Advantage members ranging between 125,000 and 135,000, total revenues ranging between $1.45 billion and $1.55 billion, medical margin ranging between $230 million and $250 million, medical margin on a PMPM basis ranging between $165 and $175. And finally, adjusted EBITDA ranging from positive $20 million to positive $40 million. Our practice is not to provide quarterly financial guidance. However, I would encourage our analysts and investors to consider the timing of some of the bigger factors in the quarterly cadence of our EBITDA in 2024. As a reminder, our first quarter with the regular seasonal cold and flu patterns tends to be an under contributor towards our annual EBITDA. Some additional points to consider are, first, the IBNR refresh will continue on a quarterly basis in 2024. And as mentioned before, the actual claims run-out will impact the reserve amount through any potential adjustments over the next few quarters. Second, the 2024 RAF accrual will likely take place primarily in the fourth quarter as it did in 2023 and not smoothly across the calendar year as previously believed. Finally, the benefits of the medical cost reductions that are new for this year will be mostly visible in the latter half of the year, although potentially some in the second quarter. I want to finish by mentioning that our cash flow used in operations in the fourth quarter was approximately negative $16 million, substantially better than at the start of the year. I'm very pleased with the recent close of the $25 million in notes that, on a pro forma basis, should leave us with over approximately $55 million in cash at the end of the quarter. And with that, I'd like to thank you all again for taking the time to hear about the P3 story and will hand off to Dr. Bacchus for more additional detail around early 2024 observations.

Thank you, Atul. Like many of our peers in the value-based care space, P3 also experienced increased fourth quarter costs, but specifically in December of 2023. This was due to COVID and flu exacerbations and Part B costs. However, beginning in January, we saw a return to seasonally adjusted normalization, including more normalized inpatient and outpatient utilization. In fact, in January, we saw a 6.7% reduction in hospital admissions and a 6.6% decrease in emergency department visits since December, and a 26% decrease in net expense from December of 2023 through January of 2024. Another way that P3 has been able to generate medical cost savings is through the tight utilization management of our delegated lives, which makes up approximately 30% of our total lives. Prior authorization and concurrent review activities on procedures like diagnostic imaging, high-cost Part B medications, steering to appropriate sites of care for high-cost procedures, such as orthopedics, and managing admissions have all shown improved savings month-over-month—a 9.5% improvement in Part B cost avoidance from December to January. It is because of P3's philosophy to not only manage our primary care physicians with our teams, tools, and technology but to also manage our entire network of specialists and pharmaceutical costs that allow us to drive deeper relations in all of our markets. We believe that if you are managing care for patients, you must manage the entire continuum of care to drive the best outcomes at the lowest potential costs. Now I would like to turn the call over to Bill Bettermann, our Chief Operating Officer.

Thank you, Amir. I'll begin by reviewing operational activities for 2023 related to ACO REACH across all markets—the California and the Oregon markets. Our Oregon market saw a $171 PMPM capitated revenue increase from 2022 to 2023, which was a $67 million increase year-over-year, as well as a $108 PMPM improvement in medical margin year-over-year. The work done to reduce medical costs and improve revenue resulted in $21 million of EBITDA improvement year-over-year, demonstrating the effectiveness of our tools, our technology, and the teams even in a nascent market. We believe we have the ability to create significant value in a short period of time and anticipate continued performance in medical expense reduction and accurate coding and documentation for our patients with chronic health conditions, ensuring the Oregon market reaches profitability in 2024 while simultaneously improving quality scores. We continue to see significant member growth in Oregon. From 2023 to early 2024, we expanded from five counties to eleven counties, growing from 21,858 members to 33,229 members, which is a 52% increase in membership year-over-year. We attribute this growth to our strong partnerships with key health plans across the state and our proven delivery model. In 2023, our California market had a $931 PMPM medical expense compared to $1,014 PMPM medical expense in 2022, representing an 8.1% improvement year-over-year. California's medical margin in 2022 was a $57 PMPM loss compared to a positive $215 PMPM in 2023, which is a staggering $272 PMPM improvement leading to a $32 million improvement in medical margin year-over-year. The California market had $9.2 million EBITDA in 2023 compared to a negative $13 million EBITDA in 2022, which is a $22 million EBITDA improvement year-over-year. We achieved these results by optimizing our plan mix, reducing medical expense, and accurately coding conditions of our patients, allowing us to grow profitably. We expect to add several new health plans in 2024, continuing to build on our 2023 profitable growth. Through our ACO REACH program, we continue to cement our value-based care programs with PCPs. In January 2024, we recorded 10,505 lives, up from 7,510 lives in 2023. These lives are expected to increase substantially over the coming years since we began expanding into ACO REACH during 2023. We have grown to 32 provider groups, which is a 15% increase year-over-year. We are able to improve engagement across patient panels for our affiliates within the Medicare ACO REACH program and improve the overall cost of care. We view the increasing engagement as a promising signal for the adoption of value-based care models and for the future of our clinical, financial, and operational performance. Thank you all once again for your interest in the P3 story. And with that, I'm going to turn it back to the operator to open the floor to questions.

And today's first question comes from Brooks O'Neil with Lake Street Capital Partners.

We appreciate all the color. I might have missed it, but I don't think I heard any discussion about the element talked about in the 8-K a few weeks ago about growing concern language. Would you say we should expect to read that in the 10-K? Or are you in better shape today based on your and your auditors assessment?

Yes. Brooks, just a quick—this is Atul speaking. A quick word on that. The guidance we've received from external counsel suggested that we include that language in the filing and did so as we believe that was the appropriate protocol. But the going concern language is not new. That was in prior filings as well. So this is not a new development for the company at all. Just wanted to make that clear. But as far as going forward, the expectation for that to be removed will be a decision that's made by the auditors, not necessarily by us. The expectation is that there will need to be a period, and that's a bit unclear as to how many quarters of profitability or at least some calculus around medical margin positivity. And as you know, we posted some meaningful medical margin, $135 million this year. So that will need to continue for some period of time until they feel comfortable in removing that. Unfortunately, that's not something that we can actually just remove at our own will.

That's how auditors think, I guess, right, guys?

It's part of their requirements. So I'm not suggesting it's appropriate. The company has made losses, and that's the reason for the disclosure.

Sure. Let me ask two more quick ones, hopefully. First one is, obviously, the December increase in medical expense is probably more seasonally related and episodic than it is related to some of the factors that you attempt to control in the P3 model, but would you say there are elements in your model that can protect you or minimize the impact of these seasonal factors? Or should we expect that to be a possible recurring factor depending on what cold and flu season is like in any particular year?

Brooks, this is Amir. So I'll answer that question. So yes, you will definitely see the seasonality that happens through basically in the fourth quarter and part of the first quarter of every year in regards to increasing exacerbations of flu, etc. Obviously, this year, we had the combination of a mild or moderate COVID spike with the flu that led to an overall increase in admissions. So we did see that. P3, obviously, we work collectively not only with our plans and our providers to make sure we improve access during that period of time. because that engagement is always important with our providers to improve access, which is something we can do to help decrease the potential risk of increasing costs that we see in those seasonality months. But in addition to that, as we've talked about before, it's making sure that we can look at more delegation as we move forward into '25, so we can have more control over overall medical costs, not necessarily just spikes or just increased medical illness.

Sure. That makes sense. Let me ask one more, quick one. Do you guys anticipate a substantial change in your business relative to the changes in the CMS risk methodology expected or implemented in 2024? Do you expect any further substantial changes in 2025? I know it's early, but what are you hearing? What do you see?

Brooks, this is Bill Bettermann. So as we've stated in the past, the changes from version 24 to 28, we do expect some slight headwinds, not nearly as impactful as we're seeing with some of our competitors or others in the sector and in the industry. So we will continue to monitor that closely. But there are a couple of things that we've talked with you and others about that we think really differentiate us. So one of these factors that helps us is the education work that we do with our providers and affiliates. So we have a very robust program that's ongoing. And obviously, there's cost and people associated with that. And that's why we said there's still some headwind to this as we have to prepare for additional work around this area throughout the rest of this year and into '25. But we do anticipate it will continue as a slight headwind for the foreseeable future.

And our next question today comes from Josh Raskin at Nephron Research.

Just trying to dig into the medical expense here, obviously way above what we were looking for. So the MLR was reported at 107%. I know there was that $30 million and the $10 million, maybe $40 million of what you guys deem to be sort of unusual or out of period expenses. But even without that, the MLR is still in the sort of mid-high 90s. And so I understand a couple of the metrics you talked about for January. But what gives you confidence that you've got medical expense that's going to trend more in line with expectations, and how are you doing that, especially with some of the change outage that impacted claims for February and March? Or just what data are you getting from the plans? And are you doing anything differently from a member perspective around inpatient utilization or ER visits to monitor your membership?

Yes. Josh, it's Amir again. So a couple of things. First of all, when you look at our MLR and things like that, part of the MLR increase, what we've seen year-over-year came a lot from the ACO REACH as well. So our ACO REACH population has a much higher med expense overall than what we've seen in MA, which has driven up the overall cost. Even though our funding has actually been able to offset that from what we've seen from what we're getting an ACO versus MA. So it's still, for us, very good business for us to continue to take on even with the higher cost that we see in that cohort or population. But in addition to that, as we look forward to the things that we're doing collectively and working with our plans and the communication with our plans is to do those very things that we've talked about before and get in front of that medical expense, particularly in the things we have visibility to from whether it's people asking on our 30% or delegated lives for ex-procedures, the Part B cost expenditures, etc. And as you heard me say, the Part B expenditures have been significantly higher, I think, throughout all the markets, not necessarily just P3, but everybody. So these things will require more control and management and we look forward to working with our plans to do that very thing besides just where we're delegated.

Josh, this is Bill Bettermann. I just want to add to what Dr. Bacchus had shared. One of the things from an operational perspective is this year we've really doubled down and focused on some things around medical expense reduction that we were looking at last year, but we've got some new cohorts of patients that we can look at in addressing early in the year. So we have new programs that are available to our patients that weren't available at the beginning of 2023. So we're excited about some of our opportunities that we didn't have in front of us to reduce that cost that we saw last year.

Got you. And how much—I'm trying to figure out how much was December. So what was the MLR, I guess, in October and November versus what December was?

October, November, I'm going to go and give you some general guidance. I don't have the numbers exactly in front of me, but they were generally consistent with what we saw in the third quarter. And then the balance obviously was in December and that blended out for the entire quarter.

And when you said med claims expense was down 26% in January versus December, is that including all the extra—the $40 million of items in December? Or is that sort of a more normalized number?

That was straightforward medical expense that we saw in— from December to the drop that we saw in January since we were able to get completion or more completion on the January numbers, and obviously, February and March are still—we're still waiting for all the numbers to come back in. But definitely, from December, it was a 26% drop that we saw in utilization into January.

And the December included the write-down, the $10 million write-down of reserves?

No, it did not.

Okay. So just expense. And then just last one. I heard the $55 million of expected cash at the end of the quarter. Do you have an expectation of cash on the balance sheet at end of year?

We don't. And we talked about it in the past, it's rather difficult to get the timing right when you're forecasting cash to that level of precision. So we haven't really put out any specific guidance on end-of-year cash for that reason. But as I said earlier, I think the addition of the cash from this note offering provides us with a nice cushion. It gives us some protection from unforeseen and unexpected things happening in the year. But all in all, we feel pretty good about where we are.

And our next question today comes from David Larsen with BTIG.

Can you talk about the medical trend like when we last spoke? I think you mentioned medical trend was actually minus 1% for members that have been on the platform for a year or more. Do you have—did you highlight what the medical trend was in the quarter? Or what it's trending at?

Dave, this is Amir. I do not have the medical trend right in front of me right now because of the December blip, but we can get that to you. So we can have a call offline and we can show you what that was.

Okay. And then I'm sorry, how much revenue pushed, I think, from 4Q into 2024?

It's not really pushed. Dave, are you asking about how much did we accrue in the fourth quarter for our sweep revenue?

Yes.

The $20 million. Yes. So the amount we booked in the fourth quarter was relatively consistent with the numbers that we've been talking about.

Okay. And then can you talk about the nature of the claims? What was it? Were they hips? Were they knees? Was it Medicare Advantage? Was it cough/cold flu? Because, I mean, we had a call with an expert this afternoon, and he specializes in this space and he's saying that these medical expenses are going to trend higher for the next year. Just any color on what were the costs?

Yes. So David, this is Amir again. So a number of things. As I set up front, obviously, COVID and flu—that's one of them. The Part B cost, which is a large bag, right, in the Part B cost deal with everything from what you see from whether it's elective procedures and/or Part B drug utilization, all of those together led to elevated Part B costs that we saw towards the end of the year in December. So we can sit there and try to wrestle out as far as how many actual procedures versus admissions and things like that. We absolutely know we were elevated due to some of those things. But for us, it's making sure that we can continue to evaluate under the changes that we see within health plans and what we can do, especially from the delegated standpoint, to have more control versus just somehow some plans having more open referrals to specialists without being able to do that prior authorization and evaluation. So it is kind of a mixed bag. So you can see it's not just one thing that was Part B drugs or just outpatient or elective procedures. We definitely do know it was, to some degree, from the COVID and flu combination that led to those things in December.

Okay. And then what are your expectations for revenue in 2024 on a PMPM basis, like in terms of health plans raising premiums, most of them, I think, are saying that they got to raise premiums significantly to account for the utilization and the RAF scores, like just thoughts there and then as well as the impact of coding and perhaps your ability to capture more of the premium? Are there clauses in your contracts? I say, hey, if medical claims expenses are higher than expected, you can get more of the premium? Just any thoughts there would be great.

So David, Sherif here. So we definitely are able to renegotiate a contract at any time. I mean, no one can stop us from doing that. And most health plans understand the situation. But the example that I would like to share with you, and the risk for analysts here that we were able to do any year in this past year and the prior year is to look at certain benefits and then limit our liability or exposure to the downside. For example, we noticed like most of the other health plans that don't benefit usage has been on the rise and increase. And as part of our DOFR or Division of Financial Responsibility to take risk on these ancillary services or benefits. So we went to the two largest health plans that we contract with, and we showed them the trend and we showed them the cost. And we were able to flatten the liability and a cost to the prior year per member per month cost, and anything above that was removed from our percentage of premium to the health plan percentage of premium. Same thing with the flex cards; some health plans that increased the margin or the size of the benefit of the flex card, we were able to go to the health plan and say we’re going to pay up until it was last year; whatever you increased this year was yours, and health then agreed to that because they knew that they wanted to acquire market share. So they were able to observe it. Does that answer your question?

It does. And then just one final one, and I'll hop back in the queue. Thank you for being so patient with me here. I guess in the last two weeks of February and in the first two weeks of March, did you receive—I mean, I guess you must have received additional data on December utilization, and that's what drove the spike relative to expectations. Is that correct?

That's correct.

Okay. All right. So it takes at least, we'll call it, 2.5 months or 90 days to get all the data. So if we're thinking about January, like do you have all the data for January? Or are there still a couple of files you're waiting for?

So we have a lot of data for January, and you understand that it was never going to be complete until like 6 or 9 months down the road. However, we have enough indication to calculate the liability and IBNR and overall medical cost.

And our next question today comes from Ryan Daniels from William Blair.

This is Jack Senft, on for Ryan Daniels. Most of my questions have been answered already, but I just wanted to go back to the medical margin. I mean it is expected to increase pretty substantially this year. So just kind of curious what the largest driver is here. Is it more of the material lives just starting to shine through versus less new lives coming on? Or—is it really a majority coming from ACO REACH that could be additional upside? Just kind of curious if you can double-click on that again.

Yes. Certainly, this is Amir again. So a couple of things. You're absolutely right as far as the ACO REACH with the higher revenue, which is great, and we appreciate seeing that. However, as far as our number of lives that are persistent, yes, through this AEP, we actually had an even improved number of persistent lives compared to previous years. So we're actually looking at probably 92% persistency, which gives us, I should say, makes us more excited to achieve that medical margin because of that persistency. So because it's been much better than last year, it gives us much more opportunity to continue to work with those patients to improve not only the documentation and understand their diagnosis burden but at the same time, get them more plugged in, especially with their providers in the care model. And as we do that, we will see that margin increase to that margin that we described to the $230 million to $250 million range.

Okay. Understood. And just a quick follow-up. Can you guys just talk about the demand you're seeing from health systems and kind of how those partnerships have progressed? I think that's a pretty good opportunity. So just kind of curious how those are shaping up for this year and if you're still generally seeing demand from health systems?

Yes. Thanks, Jack. Sherif here. Yes, we continue to see demand from the health system. And as you all may or may not know, 61% of primary care are employee doorstep through health systems in this country. So that's why we're focusing on the joint venture and strategic partnership opportunities with health systems overall because of the access to that large pool of providers and physicians that are looking for improved working conditions, workflow and returning to the joy of practicing medicine as well. And we believe that our model will provide and support that.

All right. Thank you. Well, that appears to end our question-and-answer session. So I'd like to turn the conference back over to the management team for any closing remarks.

Great. Thank you very much, operator. So for everybody, I wanted to recap what we discussed today with the group: we had a very strong growth year in 2023 with a 21% increase in top line revenue. And we're reaffirming and confirming our 2024 full guidance of positive EBITDA of $20 million to $40 million. Thank you very much, and have a great afternoon.

Thank you, sir. This concludes today's conference call. We thank you all for attending today's presentation. You may now disconnect your lines and have a wonderful day.